Suppr超能文献

人体内鹅去氧胆酸的生物合成:5β-胆甾烷-3α,7α-二醇的立体特异性侧链羟基化作用

Biosynthesis of chenodeoxycholic acid in man: stereospecific side-chain hydroxylations of 5beta-cholestane-3alpha,7alpha-diol.

作者信息

Shefer S, Cheng F W, Batta A K, Dayal B, Tint G S, Salen G

出版信息

J Clin Invest. 1978 Sep;62(3):539-45. doi: 10.1172/JCI109158.

Abstract

Stereospecific side-chain hydroxylations of 5beta-cholestane-3alpha, 7alpha-diol were studied in mitochondrial and microsomal fractions of human liver. Incubation of 5beta-cholestane-3alpha, 7alpha-diol resulted in hydroxylations at C-12, C-24, C-25, and C-26. Hydroxylations at C-24 and C-26 were accompanied by the introduction of additional asymmetric carbon atoms at C-24 and C-25 respectively, that led to the formation of two distinct pairs of diastereoisomers, namely 5beta-cholestane-3alpha, 7alpha,24-triols (24R and 24S) and 5beta-cholestane-3alpha, 7alpha,26-triols (25R and 25S). A sensitive and reproducible radioactive assay to measure the formation of the different biosynthetic 5beta-cholestanetriols was developed. Optimal assay conditions for human mitochondrial and microsomal systems were tentatively established.The mitochondrial fraction was found to predominantly catalyze the 26-hydroxylation of 5beta-cholestane-3alpha, 7alpha-diol with the formation of the 25R-diastereoisomer of 5beta-cholestane-3alpha, 7alpha,26-triol as the major product. In the microsomal fraction, on the other hand, 25-hydroxylation was more efficient than 26-hydroxylation and accounted for 6.4% of the total hydroxylations. The microsomes catalyzed the formation of both diastereoisomers of 5beta-cholestane-3alpha, 7alpha,26-triol (25R and 25S, 4.2 and 1.6% respectively). These experiments suggest that the initial step in the degradation of the steroid side chain during the biosynthesis of chenodeoxycholic acid in man is mediated by the mitochondria, and involves the formation of the 25R-diastereoisomer of 5beta-cholestane-3alpha, 7alpha,26-triol. The role of the microsomal 25- and 26-hydroxylated intermediates requires further exploration.

摘要

在人肝脏的线粒体和微粒体组分中研究了5β-胆甾烷-3α,7α-二醇的立体特异性侧链羟基化反应。5β-胆甾烷-3α,7α-二醇的孵育导致了C-12、C-24、C-25和C-26位的羟基化。C-24和C-26位的羟基化分别伴随着在C-24和C-25位引入额外的不对称碳原子,这导致形成了两对不同的非对映异构体,即5β-胆甾烷-3α,7α,24-三醇(24R和24S)以及5β-胆甾烷-3α,7α,26-三醇(25R和25S)。开发了一种灵敏且可重复的放射性测定法来测量不同生物合成的5β-胆甾烷三醇的形成。初步确定了人线粒体和微粒体系统的最佳测定条件。发现线粒体组分主要催化5β-胆甾烷-3α,7α-二醇的26-羟基化反应,形成5β-胆甾烷-3α,7α,26-三醇的25R-非对映异构体作为主要产物。另一方面,在微粒体组分中,25-羟基化比26-羟基化更有效,占总羟基化反应的6.4%。微粒体催化形成5β-胆甾烷-3α,7α,26-三醇的两种非对映异构体(25R和25S,分别为4.2%和1.6%)。这些实验表明,在人体内鹅去氧胆酸生物合成过程中甾体侧链降解的初始步骤由线粒体介导,并且涉及5β-胆甾烷-3α,7α,26-三醇的25R-非对映异构体的形成。微粒体25-和26-羟基化中间体的作用需要进一步探索。

相似文献

本文引用的文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验